JP7486415B2 - Ｃ５ａ活性のインヒビターでの炎症性疾患の処置 - Google Patents

Ｃ５ａ活性のインヒビターでの炎症性疾患の処置 Download PDF

Info

Publication number
JP7486415B2
JP7486415B2 JP2020502768A JP2020502768A JP7486415B2 JP 7486415 B2 JP7486415 B2 JP 7486415B2 JP 2020502768 A JP2020502768 A JP 2020502768A JP 2020502768 A JP2020502768 A JP 2020502768A JP 7486415 B2 JP7486415 B2 JP 7486415B2
Authority
JP
Japan
Prior art keywords
antibody
amino acid
binding
human
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020502768A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515643A5 (https=
JP2020515643A (ja
Inventor
レンフォン・グオ
ニールス・ツェー・リーデマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
InflaRx GmbH
Original Assignee
InflaRx GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by InflaRx GmbH filed Critical InflaRx GmbH
Publication of JP2020515643A publication Critical patent/JP2020515643A/ja
Publication of JP2020515643A5 publication Critical patent/JP2020515643A5/ja
Priority to JP2022127667A priority Critical patent/JP2022176946A/ja
Application granted granted Critical
Publication of JP7486415B2 publication Critical patent/JP7486415B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020502768A 2017-04-03 2018-01-03 Ｃ５ａ活性のインヒビターでの炎症性疾患の処置 Active JP7486415B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022127667A JP2022176946A (ja) 2017-04-03 2022-08-10 Ｃ５ａ活性のインヒビターでの炎症性疾患の処置

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17164573 2017-04-03
EP17164573.2 2017-04-03
EP17177657 2017-06-23
EP17177657.8 2017-06-23
EP17189938.8 2017-09-07
EP17189938 2017-09-07
PCT/EP2018/050146 WO2018184739A1 (en) 2017-04-03 2018-01-03 Treatment of inflammatory diseases with inhibitors of c5a activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022127667A Division JP2022176946A (ja) 2017-04-03 2022-08-10 Ｃ５ａ活性のインヒビターでの炎症性疾患の処置

Publications (3)

Publication Number Publication Date
JP2020515643A JP2020515643A (ja) 2020-05-28
JP2020515643A5 JP2020515643A5 (https=) 2021-01-07
JP7486415B2 true JP7486415B2 (ja) 2024-05-17

Family

ID=61024731

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020502768A Active JP7486415B2 (ja) 2017-04-03 2018-01-03 Ｃ５ａ活性のインヒビターでの炎症性疾患の処置
JP2022127667A Withdrawn JP2022176946A (ja) 2017-04-03 2022-08-10 Ｃ５ａ活性のインヒビターでの炎症性疾患の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022127667A Withdrawn JP2022176946A (ja) 2017-04-03 2022-08-10 Ｃ５ａ活性のインヒビターでの炎症性疾患の処置

Country Status (17)

Country Link
US (4) US10376595B2 (https=)
EP (3) EP3978523A1 (https=)
JP (2) JP7486415B2 (https=)
KR (1) KR20190138806A (https=)
CN (1) CN111108118A (https=)
AU (1) AU2018249310A1 (https=)
CA (1) CA3058023A1 (https=)
CL (1) CL2018002698A1 (https=)
DK (1) DK3411400T3 (https=)
ES (1) ES2893769T3 (https=)
IL (1) IL261809B2 (https=)
MX (1) MX2019011825A (https=)
PL (1) PL3411400T3 (https=)
SG (1) SG11201807998WA (https=)
TW (2) TWI826364B (https=)
WO (1) WO2018184739A1 (https=)
ZA (1) ZA201906485B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022176946A (ja) * 2017-04-03 2022-11-30 インフラルクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｃ５ａ活性のインヒビターでの炎症性疾患の処置

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP3973994A1 (en) 2014-06-12 2022-03-30 RA Pharmaceuticals, Inc. Modulation of complement activity
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
RU2733720C2 (ru) 2015-12-16 2020-10-06 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
KR20190093196A (ko) 2016-12-07 2019-08-08 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
TWI786132B (zh) * 2017-06-23 2022-12-11 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
WO2020112961A1 (en) 2018-11-30 2020-06-04 Chemocentryx, Inc. Capsule formulations
TW202100179A (zh) * 2019-03-08 2021-01-01 美商Ｒａ製藥公司 補體活性之調節劑
IL312955B1 (en) 2019-03-11 2026-01-01 Inflarx Gmbh Fused piperidinyl bicyclic compounds and related compounds as C5a receptor modulators
SG11202109837SA (en) * 2019-04-24 2021-10-28 Ra Pharmaceuticals Inc Compositions and methods for modulating complement activity
JP2022535411A (ja) 2019-06-04 2022-08-08 ラ ファーマシューティカルズ インコーポレイテッド 補体阻害剤による炎症性疾患治療
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
US20230050339A1 (en) * 2020-02-18 2023-02-16 Children's Hospital Medical Center Compositions and methods for treating liver disease
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
WO2022033981A1 (en) * 2020-08-12 2022-02-17 Innate Pharma Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab
JP7839157B2 (ja) 2020-10-28 2026-04-01 ケモセントリックス， インコーポレイテッド 化膿性汗腺炎を処置する方法
CN116529241A (zh) * 2020-10-28 2023-08-01 坎莫森特里克斯公司 治疗化脓性汗腺炎的方法
CA3173944A1 (en) 2021-01-13 2022-07-21 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
US12433657B2 (en) 2022-01-04 2025-10-07 B2M Medical, Inc. Planar-shaped thermal balloon for mesenteric fat reduction
CN116036233A (zh) * 2023-01-10 2023-05-02 中山大学附属第八医院（深圳福田） 小分子化合物pmx 53在制备抑制血管钙化和血管纤维化药物中的应用
JP2026510820A (ja) 2023-03-16 2026-04-10 アムジェン インコーポレイテッド 化膿性汗腺炎診断用バイオマーカー
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
AU2024324780A1 (en) * 2023-08-16 2026-02-05 Inflarx Gmbh Fused piperidinyl bicyclic and related compounds for use in the treatment of diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015140304A1 (en) 2014-03-20 2015-09-24 Inflarx Gmbh Inhibitors of c5a for the treatment of viral pneumonia
JP2016518331A (ja) 2013-03-14 2016-06-23 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 補体成分Ｃ５ｉＲＮＡ組成物及びその使用方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
WO1991004014A1 (en) 1989-09-21 1991-04-04 Synergen, Inc. Method for transporting compositions across the blood brain barrier
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AUPR833401A0 (en) 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
HUE038239T2 (hu) 2004-02-12 2018-10-29 Archemix Llc Komplementrendszerrel összefüggõ rendellenességek kezelésében alkalmazható aptamer terapeutikumok
SG151283A1 (en) 2004-03-26 2009-04-30 Promics Pty Ltd Treatment of neurological conditions using complement c5a receptor modulators
CN101553244B (zh) 2006-07-21 2013-01-02 普罗米克斯有限公司 内膜增生和相关病状的治疗
ES2570153T3 (es) * 2006-08-22 2016-05-17 Novo Nordisk As Anticuerpos anti-C5aR con propiedades mejoradas
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
WO2011056972A2 (en) * 2009-11-04 2011-05-12 Case Western Reserve University Compositions and methods of treating a t cell mediated disorder
RS54998B1 (sr) 2008-12-22 2016-11-30 Chemocentryx Inc Antagonisti c5ar
GB0905790D0 (en) 2009-04-03 2009-05-20 Alligator Bioscience Ab Novel polypeptides and use thereof
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
RS56332B1 (sr) 2010-06-24 2017-12-29 Chemocentryx Inc Antagonisti c5ar
DK3424953T3 (en) 2011-06-06 2020-11-02 Novo Nordisk As Terapeutiske antistoffer
JP2016523829A (ja) 2013-05-08 2016-08-12 ノヴォ ノルディスク アー／エス Ｃ５ａｒアンタゴニストの使用
WO2016044419A1 (en) 2014-09-16 2016-03-24 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2016061066A1 (en) 2014-10-15 2016-04-21 Alexion Pharmaceuticals, Inc. Methods of replicating a large scale eculizumab production cell culture
FR3030515B1 (fr) * 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
EP3313437A1 (en) 2015-06-26 2018-05-02 Alexion Pharmaceuticals, Inc. A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
EP3439658B1 (en) 2016-04-04 2021-11-24 ChemoCentryx, Inc. Soluble c5ar antagonists
TWI826364B (zh) * 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
IL312955B1 (en) 2019-03-11 2026-01-01 Inflarx Gmbh Fused piperidinyl bicyclic compounds and related compounds as C5a receptor modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016518331A (ja) 2013-03-14 2016-06-23 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 補体成分Ｃ５ｉＲＮＡ組成物及びその使用方法
WO2015140304A1 (en) 2014-03-20 2015-09-24 Inflarx Gmbh Inhibitors of c5a for the treatment of viral pneumonia

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Ｆｒｏｎｔ．Ｐｈａｒｍａｃｏｌ．、２０１７年、Ｖｏｌ．８、♯１０
Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｊｏｕｒｎａｌ ｏｆ Ｒｈｅｕｍａｔｏｌｏｇｙ、２０１７年８月２０日、Ｖｏｌ．２０１７、Ａｒｔｉｃｌｅ ＩＤ ８０１８１９２
Ｊｏｕｒｎａｌ ｏｆ Ｉｎｖｅｓｔｉｇａｔｉｖｅ Ｄｅｒｍａｔｏｌｏｇｙ、２０２１年、Ｖｏｌ．１４１、ｐ．２９６６－２９６９
Ｍｏｌｅｃｕｌａｒ Ｍｅｄｉｃｉｎｅ Ｒｅｐｏｒｔｓ、２０１５年２月４日発行、Ｖｏｌ．１１、Ｎｏ．６、ｐ．４１８３－４１８９
Ｎａｔｕｒｅ Ｒｅｖｉｅｗｓ、２０１５年、Ｖｏｌ．１４、ｐ．８５７－８７７
Ｓｔｕｄｙ ＮＣＴ０３００１６２２ ｏｎ Ｄａｔｅ：Ｍａｒｃｈ ２０、２０１７（ｖ３）、Ｃｌｉｎｉｃａｌ Ｔｒｉａｌｓ．ｇｏｖ［ｏｎｌｉｎｅ］、２０１７年３月２０日
炎症、１９８６年、Ｖｏｌ．６、Ｎｏ．１、ｐ．５－１４

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022176946A (ja) * 2017-04-03 2022-11-30 インフラルクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｃ５ａ活性のインヒビターでの炎症性疾患の処置

Also Published As

Publication number Publication date
US11464868B2 (en) 2022-10-11
TW201836641A (zh) 2018-10-16
WO2018184739A1 (en) 2018-10-11
KR20190138806A (ko) 2019-12-16
CL2018002698A1 (es) 2018-12-07
EP3411400B1 (en) 2021-09-22
TW202348249A (zh) 2023-12-16
CN111108118A (zh) 2020-05-05
US20200061202A1 (en) 2020-02-27
ES2893769T3 (es) 2022-02-10
US20210046191A1 (en) 2021-02-18
US10376595B2 (en) 2019-08-13
US20180282425A1 (en) 2018-10-04
US11890349B2 (en) 2024-02-06
JP2020515643A (ja) 2020-05-28
MX2019011825A (es) 2020-12-11
CA3058023A1 (en) 2018-10-11
EP4272821A3 (en) 2024-01-03
IL261809B1 (en) 2023-12-01
TWI826364B (zh) 2023-12-21
IL261809A (en) 2018-11-29
IL261809B2 (en) 2024-04-01
EP3411400A1 (en) 2018-12-12
US20180280530A1 (en) 2018-10-04
EP4272821A2 (en) 2023-11-08
DK3411400T3 (da) 2021-10-11
AU2018249310A1 (en) 2019-10-17
US11273225B2 (en) 2022-03-15
PL3411400T3 (pl) 2021-12-20
JP2022176946A (ja) 2022-11-30
SG11201807998WA (en) 2018-12-28
EP3978523A1 (en) 2022-04-06
ZA201906485B (en) 2021-08-25

Similar Documents

Publication Publication Date Title
JP7486415B2 (ja) Ｃ５ａ活性のインヒビターでの炎症性疾患の処置
JP7502865B2 (ja) Ｃ５ａ活性のインヒビターでの炎症性疾患の処置
KR102645242B1 (ko) 염증 질환의 치료 방법
CN102741283B (zh) 具有高阻断活性的抗-C5a结合部分
KR20210114964A (ko) 화농성 한선염 치료에 사용하기 위한 항-cd40 항체
JP2023518884A (ja) コロナウイルス感染の処置のためのＣ５ａのインヒビター
HK40070841A (en) Treatment of inflammatory diseases with inhibitors of c5a activity
HK40101423A (en) Treatment of inflammatory diseases with inhibitors of c5a activity
US20240043562A1 (en) Musk activation
EA043076B1 (ru) Лечение воспалительных заболеваний с помощью ингибиторов активности c5a
HK40000612B (en) Treatment of inflammatory diseases with inhibitors of c5a activity
RU2801531C2 (ru) Способы лечения или предотвращения астмы посредством введения антагониста il-4r

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220810

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220810

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220830

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220906

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220930

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221004

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240507

R150 Certificate of patent or registration of utility model

Ref document number: 7486415

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150